Select
Home
About Us
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Corporate Governance
Development
Assets in Development
Deoxymab 3E10
PAT SC1
Investors
Analysts Reports
Annual Reports
Financial Reports 2020
Financial Reports 2019
Financial Reports 2018
Financial Reports 2017
Financial Reports 2016
Join Our Mailing List
News & Media
Market Announcements 2020
Market Announcements 2019
Market Announcements 2018
Market Announcements 2017
Newsletters
In the News
Media Contact
Subscribe
Contact
ASX: PAB
LATEST NEWS
3 August 2020
Entitlement Offer Results and Shortfall Notification
22 July 2020
Investor Update
22 June 2020
Entitlement Offer Prospectus
22 June 2020
$4.29 Million Fully Underwritten Rights Issue
DEOXYMAB 3E10 INTRODUCTION
DEOXYMAB 3E10 PLATFORM
